Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

98 sites for NCT04607668

Microsatellite Stable (MSS)

Colorectal Adenocarcinoma

bevacizumab, +2 more drugs

chemotherapy, +1 more type

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

83 sites for NCT02715284

Deficient DNA Mismatch Repair (dMMR), +8 more biomarkers

Endometrial Carcinoma, +11 more conditions

dostarlimab

immunotherapy

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

1 site for NCT05061017

Microsatellite Stable (MSS)

Colorectal Carcinoma, +2 more conditions

cyclophosphamide, +2 more drugs

chemotherapy, +2 more types

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

1 site for NCT05036681

Microsatellite Stable (MSS)

Endometrial Carcinoma

futibatinib, +1 more drug

immunotherapy, +1 more type

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

45 sites for NCT04463771

Deficient DNA Mismatch Repair (dMMR), +23 more biomarkers

Endometrial Carcinoma, +2 more conditions

epacadostat, +2 more drugs

immunotherapy, +1 more type

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

3 sites for NCT04907539

Microsatellite Stable (MSS), +4 more biomarkers

Colorectal Carcinoma

denosumab, +2 more drugs

immunotherapy, +1 more type

Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

72 sites for NCT04262687

Microsatellite Stable (MSS)

Colorectal Adenocarcinoma

bevacizumab, +3 more drugs

chemotherapy, +2 more types

A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer

1 site for NCT05130060

Microsatellite Stable (MSS)

Colorectal Adenocarcinoma

polyPEPI1018, +1 more drug

chemotherapy, +1 more type

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors

18 sites for NCT04895709

Microsatellite Stable (MSS)

Adenocarcinoma of the Gastroesophageal Junction, +5 more conditions

BMS-986340, +1 more drug

immunotherapy

A Study of NX-1607 in Adults With Advanced Malignancies

2 sites for NCT05107674

ER Negative, +3 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +14 more conditions

NX-1607

targeted therapy

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

51 sites for NCT03110107

Microsatellite Stable (MSS)

Colorectal Carcinoma, +2 more conditions

BMS-986218, +2 more drugs

immunotherapy

Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer

1 site for NCT04708470

CDKN2A Overexpression, +2 more biomarkers

Colorectal Carcinoma, +2 more conditions

bintrafusp alfa, +2 more drugs

immunotherapy, +1 more type